FDA Peptide Reclassification Status
A plain-English breakdown of where each peptide stands with the FDA, what reclassification means, and what to expect.
Important Context
The FDA uses a three-category interim classification system for bulk drug substances nominated for compounding under Section 503A and 503B:
Eligible for interim enforcement discretion. FDA will NOT take enforcement action — compounding permitted.
Significant safety risks identified. NOT eligible — FDA WILL consider enforcement action.
Insufficient supporting information. NOT eligible for interim discretion.
Current Peptide Classifications
| Peptide | Classification | Date Added | Status |
|---|---|---|---|
| BPC-157 | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| TB-500 (Thymosin Beta-4 fragment) | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| Ibutamoren (MK-677) | Category 2 | Sept/Dec 2023 | Awaiting Reclassification |
| GHK-Cu (injectable) | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| Epitalon | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| KPV | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| LL-37 | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| CJC-1295 | Safety risks list | N/A | Awaiting Reclassification |
| Ipamorelin | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
| Semax | Category 2 | Sept 29, 2023 | Awaiting Reclassification |
What Has Happened
FDA places most therapeutic peptides in Category 2 under Section 503A/503B.
RFK Jr. announces that approximately 14 peptides will move from Category 2 to Category 1.
FDA bulk drug substances page updated (administrative — no visible peptide classification changes).
As of this writing, no Federal Register notice has been published reclassifying these peptides. No formal regulatory action has been taken. All peptides referenced above remain Category 2. Check FDA.gov for the latest updates.
What This Means for Patients
While political signals are encouraging, no peptide has been formally reclassified from Category 2 to Category 1. The formal reclassification process typically requires a Federal Register notice, a public comment period (60-90 days), review of comments, and a final rule publication.
Signal Rx is positioned to activate peptide therapy protocols as soon as regulatory conditions allow. Our physician-supervised platform, AI-personalized protocols, and pharmacy partnerships are ready. We continue to monitor FDA developments daily.
Be First When It Happens
Take the free assessment now so your protocol is ready the moment reclassification goes live. No commitment required.
This page is for informational purposes only. Signal Rx does not provide legal or regulatory advice. Information is current as of April 2026 and subject to change.